Loxo Oncology at Lilly (United States)

Recent papers from Loxo Oncology at Lilly (United States)

1. 72P Exploratory biomarker analysis from a phase Ib/II trial of zanidatamab (zani) + evorpacept (evo) in patients (pts) with HER2+ metastatic breast cancer (mBC)ESMO Open · 2026
2. Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancernpj Breast Cancer · 2026
3. Patient-reported, psychosocial and health economic outcomes in mild to moderate Friedreich's ataxia: baseline results of the PROFA studyThe Lancet Regional Health - Europe · 2025
4. Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agentsNephrology Dialysis Transplantation · 2025
5. Nephrotoxicity of conventional chemotherapeutics: part II—non-platinum agents and miscellaneous nephrotoxic drugsNephrology Dialysis Transplantation · 2025
6. Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaBlood · 2025
7. Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 MutationsClinical Cancer Research · 2025
8. Instrument-agnostic Machine Learning Framework for Accurate Prediction of Functional Groups from Tandem Mass Spectrometry2025
9. C/EBPβ-mediated PARP1 Suppression Drives Tumor Progression of Aneuploid Cells2025
10. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 studyHaematologica · 2025
11. Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphomaLeukemia & lymphoma/Leukemia and lymphoma · 2025
12. Assessing the impact and risk of immunomodulatory compounds on pregnancyJournal of Reproductive Immunology · 2025
13. A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaCancer · 2025
14. Episiotomy to prevent obstetric anal sphincter injuries during instrumental delivery in nulliparous women: a national prospective comparative cohort studyAmerican Journal of Obstetrics and Gynecology · 2025
15. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationEuropean Journal of Cancer · 2025
16. A New Player in the International Bond Market: Comparing the Macroeconomic Determinants of Foreign-Currency Denominated Debt Before the Inclusion of the Renminbi in the SDREmerging Markets Finance and Trade · 2024
17. Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanomaCell Reports Medicine · 2024
18. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trialHaematologica · 2024
19. Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyeJHaem · 2024
20. Randomized Phase III SIERRA Trial of ¹³¹I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLJournal of Clinical Oncology · 2024